NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Attovia Therapeutics

Attovia Therapeutics

Private
San Carlos, CaliforniaHealthcare & Life Scienceshttps://www.attovia.com/

Last Round

Series C

Apr 15, 2025

Total Funding Raised

$315M

Company Overview

Attovia Therapeutics is a biotechnology company that develops precision biologics and multispecific therapeutics for immune-mediated diseases and oncology.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biotechnologybiotechdrug discoveryclinical trialsbiopharmaceuticalpruritusimmune-mediated diseasebiologicssmall moleculeATTOBODYinitial public offeringIPOclinical-stage biotechdrug pipelinebiotech IPO

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Attovia Therapeutics Comparables

Compare Attovia Therapeutics with similar companies based on industry and business-model similarity.

Attovia Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Santa Ana Bio
79%
Bambusa Therapeutics
79%
Apogee Therapeutics
77%

Attovia Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series CApr 15, 2025
Series BMay 9, 2024
Series AFeb 8, 2024
Series AJun 20, 2023

Key People

Founding team and executive leadership

Tao Fu

Chief Executive Officer

Executive Team

Hangjun Zhan

Chief Technology Officer

Executive Team

Steven Chan

Chief Financial Officer

Executive Team

Attovia Therapeutics Investors

Notable investors and investment history

Attovia Therapeutics investors
InvestorRounds
EcoR1 CapitalSeries C, Series B
Redmile GroupSeries B
Mirae AssetSeries C
Cormorant Asset ManagementSeries C, Series B
Vida VenturesSeries C
Deep Track CapitalSeries C
Frazier Life SciencesSeries C, Series B, Series A

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 13, 2025

    Partnered with SciNeuro Pharmaceuticals on a neurology target.

  • Apr 15, 2025

    $90M round raised.

Attovia Therapeutics Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Attovia Therapeutics Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Attovia Therapeutics's valuation, stock price, and market status.

Firmographic Details

HeadquartersSan Carlos, California
Employee Range53
Year Founded2023
Last FundingApr 15, 2025

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.